Catastrophic Antiphospholipid Syndrome

Catastrophic antiphospholipid syndrome (CAPS) is a rare, life-threatening manifestation of antiphospholipid syndrome characterized by rapidly developing thromboses in multiple organs, often with organ failure. Diagnosis is challenging because its presentation can resemble sepsis, disseminated intravascular coagulation, thrombotic microangiopathy, or other autoimmune emergencies. Management generally requires urgent multidisciplinary assessment, treatment of precipitating factors, anticoagulation, corticosteroids, and, where clinically appropriate, plasma exchange or intravenous immunoglobulin. Evidence is derived largely from registries, case series, and expert guidance because randomized clinical trials are difficult in this uncommon emergency.

The care landscape is shifting toward earlier recognition, standardized diagnostic criteria, and coordinated management across hematology, rheumatology, critical care, nephrology, neurology, and obstetrics. International consensus recommendations emphasize identifying triggers such as infection, surgery, medication interruption, pregnancy-related complications, and systemic autoimmune activity. Improvements in thrombosis imaging, laboratory testing for lupus anticoagulant and anticardiolipin or anti-β2-glycoprotein I antibodies, and structured case reporting are supporting more consistent evaluation, while uncertainty remains regarding optimal treatment sequencing and duration.

Artificial intelligence may assist-not replace-clinical judgment by screening electronic records for combinations of thrombocytopenia, hemolysis, renal dysfunction, neurological symptoms, thrombosis, and relevant antibody results. Machine-learning tools could also support radiology triage, identify potential treatment triggers, and improve registry-based phenotyping. However, CAPS datasets are small, heterogeneous, and vulnerable to coding errors and selection bias. Any clinical deployment requires external validation, transparent performance reporting, privacy safeguards, and prospective assessment to avoid false alerts or delayed treatment.

North America and Europe benefit from established specialist networks, intensive-care capacity, and published consensus guidance, although access to referral expertise varies. Asia-Pacific combines advanced tertiary services in some systems with substantial geographic and resource differences across countries. Latin America faces uneven access to antibody testing, plasma exchange, and specialized critical care. The Middle East has growing tertiary capability but variable referral pathways and registry coverage. Africa experiences major constraints in laboratory infrastructure, specialist availability, and timely transfer, making clinical recognition and pragmatic emergency protocols especially important. Across all regions, standardized pathways and access to essential anticoagulation are central priorities.

ASEAN cooperation can help address cross-border disparities in laboratory capacity, referral, and clinician training. BRICS members span substantial differences in health-system resources, creating opportunities for shared registries and protocol development while requiring locally adaptable implementation. The European Union can leverage harmonized clinical guidance, cross-border expertise, and collaborative research structures. G7 systems generally have strong tertiary and diagnostic capabilities but still need faster recognition and equitable access. GCC countries can build on concentrated specialist infrastructure and regional referral networks. NATO membership is not a health-system category, but its members may benefit from interoperable emergency-medicine training, logistics, and preparedness frameworks relevant to rare critical illnesses.

Australia, Canada, the United Kingdom, the United States, France, Germany, Italy, Spain, Japan, South Korea, China, India, Brazil, Mexico, and Russia differ in clinical capacity, laboratory access, referral geography, and research infrastructure. Australia and Canada must address distance to specialist centers; the United States and Western European countries can strengthen rapid multidisciplinary pathways and data interoperability. Japan and South Korea have advanced tertiary capabilities but require sustained awareness for a rare disorder. China and India would benefit from broader access to confirmatory testing and coordinated registries. Brazil and Mexico face regional disparities in specialist and critical-care access. France, Germany, Italy, Spain, and the United Kingdom can further align national guidance and reporting. Russia’s large geography makes referral coordination and consistent laboratory availability particularly important. These priorities should be interpreted alongside national clinical guidance and local resource conditions.

Industry and health-system leaders should prioritize rapid-access protocols linking emergency departments with hematology, rheumatology, intensive care, nephrology, neurology, and obstetrics. Diagnostic stewardship should include reliable antibody testing, repeat testing when clinically indicated, and clear differentiation from other thrombotic and consumptive disorders. Organizations should support prospective registries using common data definitions, monitor treatment timing and complications, and evaluate access to anticoagulation, plasma exchange, and intravenous immunoglobulin. Education should focus on precipitating-factor control, medication continuity, pregnancy-related risk, and escalation criteria. Digital tools, including AI, should be introduced only with governance, validation, auditability, and clinician oversight.

This summary uses a clinical evidence framework focused on the recognized features, diagnostic challenges, treatment principles, and health-system implications of catastrophic antiphospholipid syndrome. Interpretation should prioritize peer-reviewed studies, international consensus statements, specialist guidelines, national health authorities, and established CAPS registries. Because the condition is rare, evidence from observational cohorts, case series, and expert consensus must be distinguished from randomized evidence. Regional and country comparisons are qualitative and reflect differences in reported infrastructure, referral systems, laboratory access, and published clinical capacity; they are not estimates of disease burden or commercial performance.

CAPS remains a time-critical autoimmune thrombotic emergency in which rapid recognition, treatment of triggers, anticoagulation, immunomodulation, and coordinated organ support can be decisive. The strongest system-level opportunities are standardized pathways, dependable laboratory services, specialist collaboration, better registry data, and equitable access to critical interventions. Artificial intelligence may improve detection and research operations, but only when supported by high-quality data and rigorous clinical validation. Continued international collaboration is essential to reduce diagnostic delay and strengthen evidence for this rare syndrome.